AXSM
Axsome Therapeutics, Inc.
$255.17
+0.55%
$13.1B
No data for this timeframe.
Vol
Market Cap$13.1B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders50 funds
Inst. Value$4.2B
Inst. Activity25 buys / 12 sells
Insider Activity0B / 15S
Insider Net $-$36.9M
Reddit Sentiment50° Neutral
SEC Reports12
Press Releases3
Recent Activity
Jun 12, 2026
SEC
A cluster of insider sales at Axsome Therapeutics (AXSM) over the past week totaled ~$20.2M in open-market transactions,
CLUSTER — Impact 4/10
Jun 11, 2026
SEC
Director Roger Jeffs filed a Form 144 to sell 286 shares of Axsome Therapeutics common stock, valued at approximately $7
144 — Impact 1/10
Jun 11, 2026
SEC
CEO Herriot Tabuteau and CFO Nick Pizzie sold a combined ~$19.9M in open-market sales on June 9, 2026, following derivat
CLUSTER — Impact 4/10
Jun 11, 2026
Insider
JEFFS ROGER sold 286 shares
Director @ $249.12 ($71.2K)
Jun 10, 2026
Insider
Coleman Mark sold 643 shares
Director @ $249.00 ($160.1K)
Jun 10, 2026
Insider
Mahony Susan sold 300 shares
Director @ $246.18 ($73.9K)
Inst.
FMR LLC — ADD
1,566,995 shares ($264.9M)
Inst.
Assenagon Asset Management S.A. — ADD
865,958 shares ($146.4M)
Price Targets
$275.28
+7.9% upside
Buy
Current $255.17
Low $200.00
Median $272.00
High $380.00
21 analysts
$200.00
$380.00
Analyst Ratings
10Strong Buy
15Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 5, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight → Equal-Weight |
| May 5, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
| May 5, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| May 5, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
| May 5, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.82 ▲ +6.2% | $-1.21 — $-0.05 | 16% YoY | 8 |
| Next Q | $-0.34 ▲ +28.5% | $-0.77 — $0.62 | 64% YoY | 8 |
| Current FY | $-1.71 ▲ +30.2% | $-3.35 — $1.30 | 51% YoY | 8 |
| Next FY | $5.89 ▲ +20.4% | $1.63 — $12.53 | 445% YoY | 9 |
Latest Reports
NEUTRAL
CLUSTER
4/10
A cluster of insider sales at Axsome Therapeutics (AXSM) over the past week totaled ~$20.2M in open-market transactions,
Jun 12, 2026
NEUTRAL
144
1/10
Director Roger Jeffs filed a Form 144 to sell 286 shares of Axsome Therapeutics common stock, valued at approximately $7
Jun 11, 2026
NEUTRAL
Press
3/10
Axsome Therapeutics announced presentations of new SYMBRAVO® data at the AHS 68th Annual Scientific Meeting, including p
Jun 4, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| NOMURA ASSET MANAGEMENT CO | — | — |
| BlackRock, Inc. | $661.3M | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $347.9M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $327.5M | — |
| FMR LLC | $264.9M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 11, 2026 | JEFFS ROGER | SELL | $71.2K |
| Jun 10, 2026 | Coleman Mark | SELL | $160.1K |
| Jun 10, 2026 | Mahony Susan | SELL | $73.9K |
| Jun 10, 2026 | JEFFS ROGER | SELL | $70.4K |
| Jun 9, 2026 | TABUTEAU HERRIOT | M | $245.9K |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $4.2B total value (25,028,884 shares) as of 2026-Q1. Top holders: NOMURA, BlackRock,, VANGUARD. Net buying activity: 25 institutions added/increased vs 12 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | NOMURA ASSET MANAGEMENT CO LTD | — | $0.00 | 0.0% | — |
| 2 | BlackRock, Inc. | 3,912,844 | $661.3M | 15.6% | — |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2,058,170 | $347.9M | 8.2% | — |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 1,937,752 | $327.5M | 7.7% | — |
| 5 | FMR LLC | 1,566,995 | $264.9M | 6.3% | ADD +32.6% |
| 6 | Invesco Ltd. | 1,297,678 | $219.3M | 5.2% | ADD +28.6% |
| 7 | WELLINGTON MANAGEMENT GROUP LLP | 1,145,306 | $193.6M | 4.6% | — |
| 8 | STATE STREET CORP | 986,809 | $166.8M | 3.9% | — |
| 9 | Assenagon Asset Management S.A. | 865,958 | $146.4M | 3.5% | ADD +85.0% |
| 10 | NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 812,809 | $137.4M | 3.2% | — |
| 11 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 737,578 | $124.7M | 2.9% | DOUBLED +100.7% |
| 12 | D. E. Shaw & Co., Inc. | 603,465 | $102.0M | 2.4% | ADD +85.3% |
| 13 | BANK OF AMERICA CORP /DE/ | 598,091 | $101.1M | 2.4% | ADD +71.1% |
| 14 | FIRST TRUST ADVISORS LP | 577,479 | $97.6M | 2.3% | DOUBLED +1230.2% |
| 15 | MORGAN STANLEY | 476,701 | $80.6M | 1.9% | — |
| 16 | FRANKLIN RESOURCES INC | 438,490 | $74.1M | 1.8% | ADD +28.0% |
| 17 | Point72 Asset Management, L.P. | 424,750 | $71.8M | 1.7% | DOUBLED +2259.9% |
| 18 | GOLDMAN SACHS GROUP INC | 421,447 | $71.2M | 1.7% | — |
| 19 | Pictet Asset Management Holding SA | 415,983 | $70.3M | 1.7% | — |
| 20 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 395,118 | $66.8M | 1.6% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | ADD | 1,181,622 | 1,566,995 | +32.6% | $264.9M | 2026-Q1 |
| Assenagon Asset Management S.A. | ADD | 467,982 | 865,958 | +85.0% | $146.4M | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | DOUBLED | 367,578 | 737,578 | +100.7% | $124.7M | 2026-Q1 |
| FIRST TRUST ADVISORS LP | DOUBLED | 43,413 | 577,479 | +1230.2% | $97.6M | 2026-Q1 |
| FRANKLIN RESOURCES INC | ADD | 342,573 | 438,490 | +28.0% | $74.1M | 2026-Q1 |
| Point72 Asset Management, L.P. | DOUBLED | 17,999 | 424,750 | +2259.9% | $71.8M | 2026-Q1 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | ADD | 220,518 | 292,370 | +32.6% | $49.4M | 2026-Q1 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | ADD | 157,691 | 203,066 | +28.8% | $34.3M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | ADD | 99,916 | 176,314 | +76.5% | $29.8M | 2026-Q1 |
| 1832 Asset Management L.P. | DOUBLED | 13,700 | 143,800 | +949.6% | $24.3M | 2026-Q1 |
| MARSHALL WACE, LLP | TRIM | 320,568 | 141,236 | -55.9% | $23.9M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | TRIM | 188,258 | 134,792 | -28.4% | $22.8M | 2026-Q1 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | NEW | — | 97,550 | — | $16.5M | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 47,600 | 70,064 | +47.2% | $11.8M | 2026-Q1 |
| HSBC HOLDINGS PLC | NEW | — | 68,453 | — | $11.6M | 2026-Q1 |
| HB Wealth Management, LLC | ADD | 34,102 | 50,237 | +47.3% | $8.5M | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | ADD | 26,603 | 40,381 | +51.8% | $6.8M | 2026-Q1 |
| TD ASSET MANAGEMENT INC | TRIM | 41,972 | 27,132 | -35.4% | $4.6M | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | DOUBLED | 5,415 | 24,573 | +353.8% | $4.2M | 2026-Q1 |
| JANUS HENDERSON GROUP PLC | ADD | 15,104 | 19,052 | +26.1% | $3.2M | 2026-Q1 |
| BLAIR WILLIAM & CO/IL | TRIM | 46,840 | 16,308 | -65.2% | $2.8M | 2026-Q1 |
| FIFTH THIRD BANCORP | DOUBLED | 2,477 | 16,214 | +554.6% | $2.7M | 2026-Q1 |
| CWM, LLC | ADD | 5,149 | 7,734 | +50.2% | $1.3M | 2026-Q1 |
| &PARTNERS | DOUBLED | 1,602 | 6,137 | +283.1% | $1.0M | 2026-Q1 |
| Trexquant Investment LP | NEAR_EXIT | 49,136 | 5,935 | -87.9% | $1.0M | 2026-Q1 |
9 unique insiders with 43 transactions. Net insider value: -$36.9M ($0.00 bought, $36.9M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 11, 2026 | JEFFS ROGER | Director | SELL | 286 | $249.12 | $71.2K |
| Jun 10, 2026 | Coleman Mark | Director | SELL | 643 | $249.00 | $160.1K |
| Jun 10, 2026 | Mahony Susan | Director | SELL | 300 | $246.18 | $73.9K |
| Jun 10, 2026 | JEFFS ROGER | Director | SELL | 286 | $246.18 | $70.4K |
| Jun 9, 2026 | TABUTEAU HERRIOT | Chief Executive Officer | EXERCISE | 49,670 | $4.95 | $245.9K |
| Jun 9, 2026 | Pizzie Nick | Chief Financial Officer | EXERCISE | 33,000 | $3.50 | $115.5K |
| Jun 9, 2026 | Pizzie Nick | Chief Financial Officer | SELL | 33,000 | $240.09 | $7.9M |
| Jun 9, 2026 | TABUTEAU HERRIOT | Chief Executive Officer | SELL | 49,670 | $241.01 | $12.0M |
| Jun 9, 2026 | Mahony Susan | Director | SELL | 300 | $237.21 | $71.2K |
| Jun 8, 2026 | Coleman Mark | Director | EXERCISE | 1,429 | — | — |
| Jun 8, 2026 | Mahony Susan | Director | EXERCISE | 1,429 | — | — |
| Jun 8, 2026 | JEFFS ROGER | Director | EXERCISE | 1,429 | — | — |
| Jun 8, 2026 | Saad Mark E | Director | EXERCISE | 1,429 | — | — |
| Jun 5, 2026 | Coleman Mark | Director | AWARD | 1,721 | — | — |
| Jun 5, 2026 | Mahony Susan | Director | AWARD | 1,721 | — | — |
| Jun 5, 2026 | Saad Mark E | Director | AWARD | 1,721 | — | — |
| Jun 5, 2026 | JEFFS ROGER | Director | AWARD | 1,721 | — | — |
| Jun 2, 2026 | Coleman Mark | Director | SELL | 5,537 | $223.39 | $1.2M |
| Jun 1, 2026 | Coleman Mark | Director | SELL | 6,000 | $230.30 | $1.4M |
| May 29, 2026 | Coleman Mark | Director | SELL | 6,000 | $233.46 | $1.4M |
| May 5, 2026 | Jacobson Mark L. | Chief Operating Officer | SELL | 233 | $228.18 | $53.2K |
| May 5, 2026 | Jacobson Mark L. | Chief Operating Officer | EXERCISE | 233 | $12.95 | $3.0K |
| May 4, 2026 | Jacobson Mark L. | Chief Operating Officer | SELL | 4,517 | $227.94 | $1.0M |
| May 4, 2026 | Jacobson Mark L. | Chief Operating Officer | EXERCISE | 4,517 | $12.95 | $58.5K |
| Apr 22, 2026 | Maizel Ari | Chief Commercial Officer | EXERCISE | 7,500 | $70.73 | $530.5K |
| Apr 22, 2026 | Maizel Ari | Chief Commercial Officer | SELL | 7,500 | $182.42 | $1.4M |
| Apr 21, 2026 | Murdock Hunter R. | General Counsel | AWARD | 7,224 | — | — |
| Apr 21, 2026 | Pizzie Nick | Chief Financial Officer | AWARD | 8,188 | — | — |
| Apr 21, 2026 | Maizel Ari | Chief Commercial Officer | AWARD | 7,224 | — | — |
| Apr 21, 2026 | TABUTEAU HERRIOT | Chief Executive Officer | AWARD | 24,081 | — | — |
| Apr 21, 2026 | Jacobson Mark L. | Chief Operating Officer | AWARD | 8,669 | — | — |
| Feb 26, 2026 | Jacobson Mark L. | Chief Operating Officer | AWARD | 19,663 | — | — |
| Feb 26, 2026 | TABUTEAU HERRIOT | Chief Executive Officer | AWARD | 54,623 | — | — |
| Feb 26, 2026 | Maizel Ari | Chief Commercial Officer | AWARD | 16,385 | — | — |
| Feb 26, 2026 | Murdock Hunter R. | General Counsel | AWARD | 16,385 | — | — |
| Feb 26, 2026 | Pizzie Nick | Chief Financial Officer | AWARD | 18,570 | — | — |
| Feb 26, 2026 | Jacobson Mark L. | Chief Operating Officer | EXERCISE | 35,378 | $2.85 | $100.8K |
| Feb 26, 2026 | Coleman Mark | Director | SELL | 25,000 | $161.11 | $4.0M |
| Feb 23, 2026 | Coleman Mark | Director | EXERCISE | 6,250 | $4.95 | $30.9K |
| Feb 20, 2026 | Coleman Mark | Director | EXERCISE | 12,485 | $4.95 | $61.8K |
| Feb 10, 2026 | Coleman Mark | Director | EXERCISE | 5,193 | $8.02 | $41.6K |
| Feb 2, 2026 | TABUTEAU HERRIOT | Chief Executive Officer | EXERCISE | 32,410 | $8.02 | $259.9K |
| Feb 2, 2026 | TABUTEAU HERRIOT | Chief Executive Officer | SELL | 32,410 | $185.60 | $6.0M |
12 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 2 mixed, 8 neutral. Avg impact: 4.3/10.
NEUTRAL
CLUSTER
4/10
A cluster of insider sales at Axsome Therapeutics (AXSM) over the past week totaled ~$20.2M in open-
Jun 12, 2026
NEUTRAL
144
1/10
Director Roger Jeffs filed a Form 144 to sell 286 shares of Axsome Therapeutics common stock, valued
Jun 11, 2026
NEUTRAL
CLUSTER
4/10
CEO Herriot Tabuteau and CFO Nick Pizzie sold a combined ~$19.9M in open-market sales on June 9, 202
Jun 11, 2026
NEUTRAL
144
4/10
CEO Herriot Tabuteau files Form 144 to sell 49,670 shares of Axsome Therapeutics (~$12.2M) under a 1
Jun 9, 2026
NEUTRAL
8-K
2/10
Axsome Therapeutics adopted a formal Executive Severance and Change in Control Plan effective June 5
Jun 9, 2026
NEUTRAL
CLUSTER
4/10
CEO Herriot and CFO Pizzie exercised stock options and immediately sold the resulting shares in open
Jun 9, 2026
BULLISH
8-K
7/10
Axsome settled all SUNOSI patent litigation, granting five generic companies entry rights no earlier
Jun 3, 2026
MIXED
8-K
6/10
Axsome reported Q1 2026 revenue of $191.2M (+57% YoY), slightly above the $190.7M consensus, but net
May 4, 2026
MIXED
PRESS-RELEASE
6/10
Axsome reported Q1 2026 revenue of $191.2M (57% YoY growth, slight beat vs $190.7M consensus), but G
May 4, 2026
BULLISH
8-K
8/10
Axsome Therapeutics announced FDA approval of AUVELITY for agitation associated with dementia due to
Apr 30, 2026
NEUTRAL
DEFA14A
2/10
Axsome Therapeutics is holding its 2026 annual meeting for shareholders to vote on director election
Apr 24, 2026
NEUTRAL
PRESS-RELEASE
3/10
Axsome Therapeutics announced it will report Q1 2026 financial results on May 4, 2026, followed by a
Apr 8, 2026
NEUTRAL
3/10
Axsome Therapeutics announced presentations of new SYMBRAVO® data at the AHS 68th Annual Scientific
Jun 4, 2026
BULLISH
8/10
Axsome Therapeutics announced FDA approval of AUVELITY for agitation associated with Alzheimer's dis
May 1, 2026
BULLISH
8/10
Axsome Therapeutics announced FDA approval of AUVELITY (dextromethorphan HBr/bupropion HCl) for agit
Apr 30, 2026
Current analyst consensus: Strong Buy (93% buy). Based on 27 analysts: 10 strong buy, 15 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$275.28 mean target
+7.9% upside
Buy (1.24)
$200.00 Low
$380.00 High
| Metric | Value |
|---|---|
| Current Price | $255.17 |
| Target Low | $200.00 |
| Target Mean | $275.28 |
| Target Median | $272.00 |
| Target High | $380.00 |
| # Analysts | 21 |
| Recommendation | Buy (1.24) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.82 | $-1.21 | $-0.05 | 15.7% | +6.2% | 1↑ 3↓ | $0.2B | 48.2% | 8 |
| Next Q 2026-09-30 |
$-0.34 | $-0.77 | $0.62 | 64.4% | +28.5% | 0↑ 4↓ | $0.3B | 53.8% | 8 |
| Current FY 2026-12-31 |
$-1.71 | $-3.35 | $1.30 | 50.9% | +30.2% | 1↑ 5↓ | $1.0B | 54.4% | 8 |
| Next FY 2027-12-31 |
$5.89 | $1.63 | $12.53 | 445.1% | +20.4% | 3↑ 2↓ | $1.6B | 62.1% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.818 | |
| 7d ago | $-0.818 | |
| 30d ago | $-0.872 | +0.054 |
| 60d ago | $-0.554 | -0.263 |
| 90d ago | $-0.554 | -0.263 |
13 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 5, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| May 5, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| May 5, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| May 5, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| May 5, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| May 5, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| May 5, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 5, 2026 | Needham | MAINTAIN | Buy | Buy |
| May 4, 2026 | Jefferies | MAINTAIN | Buy | Buy |
| May 4, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 1, 2026 | Needham | MAINTAIN | Buy | Buy |
| Apr 10, 2026 | UBS | MAINTAIN | Buy | Buy |
| Mar 25, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Feb 24, 2026 | UBS | MAINTAIN | Buy | Buy |
| Feb 24, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Feb 24, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Feb 24, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 24, 2026 | Wolfe Research | INITIATE | — | Outperform |
| Feb 23, 2026 | Needham | REITERATE | Buy | Buy |
| Feb 3, 2026 | Jefferies | MAINTAIN | Buy | Buy |
| Jan 28, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Jan 21, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Jan 20, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 16, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Jan 13, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Jan 8, 2026 | Morgan Stanley | DOWNGRADE | Overweight | Equal-Weight |
| Jan 6, 2026 | UBS | MAINTAIN | Buy | Buy |
| Jan 5, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Dec 31, 2025 | Needham | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 10 | 15 | 2 | 0 | 0 | 93% | |
| May 1, 2026 | 10 | 15 | 2 | 0 | 0 | 93% | |
| Apr 1, 2026 | 9 | 15 | 2 | 0 | 0 | 92% | |
| Mar 1, 2026 | 9 | 15 | 2 | 0 | 0 | 92% | |
| Feb 1, 2026 | 9 | 15 | 2 | 0 | 0 | 92% | |
| Jan 1, 2026 | 9 | 16 | 1 | 0 | 0 | 96% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 16, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Apr 16, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Why is no one talking about $AXSM?
▲ 1
💬 1
⚡ 0.5
Jun 4, 2026
fda
Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting
<p align="justify">NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new e
Jun 1, 2026
contract
Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month
<p align="justify">NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new e
Jun 1, 2026
FDA
AUVELITY
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients i
May 29, 2026
Clinical Trial
A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy
Phase Phase 3 — COMPLETED
May 27, 2026
other
Axsome Therapeutics to Participate in Upcoming Investor Conferences
<p align="justify">NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new er
May 13, 2026
short_interest
FTD: AXSM — 57,815 shares ($13.0M) failed to deliver
Settlement: 20260513, Price: $224.03, FTD Value: $12,952,294.45, AXSOME THERAPEUTICS INC COM ST
May 12, 2026
short_interest
FTD: AXSM — 39,641 shares ($8.6M) failed to deliver
Settlement: 20260512, Price: $216.47, FTD Value: $8,581,087.27, AXSOME THERAPEUTICS INC COM ST
May 11, 2026
short_interest
FTD: AXSM — 62,981 shares ($13.7M) failed to deliver
Settlement: 20260511, Price: $217.38, FTD Value: $13,690,809.78, AXSOME THERAPEUTICS INC COM ST
May 6, 2026
FDA
AUVELITY
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients i
May 6, 2026
FDA
AUVELITY
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients i
May 5, 2026
other
Axsome Therapeutics to Participate in Upcoming Investor Conferences
<p align="justify">NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new er
May 4, 2026
earnings
Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
<p align="center"><em>Total 1Q 2026 net product revenue of $191.2 million, representing 57% year-over-year growth</em></p>
May 4, 2026
short_interest
FTD: AXSM — 13,914 shares ($2.9M) failed to deliver
Settlement: 20260504, Price: $206.53, FTD Value: $2,873,658.42, AXSOME THERAPEUTICS INC COM ST
May 4, 2026
earnings_calendar
AXSM Q1 2026 Earnings Scheduled — 2026-05-04
May 1, 2026
fda
Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader
<p align="justify">NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new er
Apr 30, 2026
fda
Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease
<p align="center"><em>AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dem
Apr 30, 2026
fda_pdufa
PDUFA: AXSM — AXS-05 in Alzheimer's disease agitation — 2026-04-30
FDA target action date 2026-04-30 for AXSM (Axsome Therapeutics, Inc.). Drug: AXS-05. Indication: Alzheimer's disease agitation. sNDA for AXS-05 for A
Apr 30, 2026
FDA
AUVELITY
Supplemental Approval — Labeling — DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE — TABLET, EXTENDED RELEASE — ORAL
Apr 8, 2026
earnings
Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4
<p align="justify">NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new
Mar 11, 2026
short_interest
FTD: AXSM — 15,412 shares ($2.6M) failed to deliver
Settlement: 20260311, Price: $166.34, FTD Value: $2,563,632.08, AXSOME THERAPEUTICS INC COM ST